306 related articles for article (PubMed ID: 37270060)
1. In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations.
Lee YS; Seki E
Cell Mol Gastroenterol Hepatol; 2023; 16(3):355-367. PubMed ID: 37270060
[TBL] [Abstract][Full Text] [Related]
2. Hepatic macrophages: Key players in the development and progression of liver fibrosis.
Cheng D; Chai J; Wang H; Fu L; Peng S; Ni X
Liver Int; 2021 Oct; 41(10):2279-2294. PubMed ID: 33966318
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.
Alqahtani SA; Chan WK; Yu ML
Clin Liver Dis; 2023 May; 27(2):211-223. PubMed ID: 37024203
[TBL] [Abstract][Full Text] [Related]
4. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?
Lee YA; Friedman SL
Antiviral Res; 2014 Jul; 107():23-30. PubMed ID: 24726738
[TBL] [Abstract][Full Text] [Related]
5. Preclinical mouse models of hepatocellular carcinoma: An overview and update.
Gu CY; Lee TKW
Exp Cell Res; 2022 Mar; 412(2):113042. PubMed ID: 35101391
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
7. The roles and mechanisms of hypoxia in liver fibrosis.
Cai J; Hu M; Chen Z; Ling Z
J Transl Med; 2021 May; 19(1):186. PubMed ID: 33933107
[TBL] [Abstract][Full Text] [Related]
8. Cellular basis of hepatic fibrosis and its role in inflammation and cancer.
Kocabayoglu P; Friedman SL
Front Biosci (Schol Ed); 2013 Jan; 5(1):217-30. PubMed ID: 23277047
[TBL] [Abstract][Full Text] [Related]
9. ADSCs-derived exosomes ameliorate hepatic fibrosis by suppressing stellate cell activation and remodeling hepatocellular glutamine synthetase-mediated glutamine and ammonia homeostasis.
Wu B; Feng J; Guo J; Wang J; Xiu G; Xu J; Ning K; Ling B; Fu Q; Xu J
Stem Cell Res Ther; 2022 Oct; 13(1):494. PubMed ID: 36195966
[TBL] [Abstract][Full Text] [Related]
10. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics.
Khairnar R; Islam MA; Fleishman J; Kumar S
Life Sci; 2023 Jan; 312():121185. PubMed ID: 36375569
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K
J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889
[TBL] [Abstract][Full Text] [Related]
12. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development.
Wallace MC; Friedman SL
Gene Expr; 2014; 16(2):77-84. PubMed ID: 24801168
[TBL] [Abstract][Full Text] [Related]
13. The multifaceted role of ferroptosis in liver disease.
Chen J; Li X; Ge C; Min J; Wang F
Cell Death Differ; 2022 Mar; 29(3):467-480. PubMed ID: 35075250
[TBL] [Abstract][Full Text] [Related]
14. Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma.
Garrido A; Djouder N
Trends Cancer; 2021 Jan; 7(1):29-36. PubMed ID: 32917550
[TBL] [Abstract][Full Text] [Related]
15. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma.
Li H
Dig Liver Dis; 2022 May; 54(5):598-613. PubMed ID: 34344577
[TBL] [Abstract][Full Text] [Related]
16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
18. LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma.
Kim YA; Park KK; Lee SJ
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326098
[TBL] [Abstract][Full Text] [Related]
19. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.
Roehlen N; Crouchet E; Baumert TF
Cells; 2020 Apr; 9(4):. PubMed ID: 32260126
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
